Many of his Multiple myeloma research pursuits overlap with Lenalidomide and Bortezomib. Hermann Einsele undertakes interdisciplinary study in the fields of Lenalidomide and Multiple myeloma through his research. He performs multidisciplinary study in the fields of Internal medicine and Pathology via his papers. Hermann Einsele applies his multidisciplinary studies on Pathology and Internal medicine in his research. He applies his multidisciplinary studies on Immunology and Virology in his research. He applies his multidisciplinary studies on Virology and Immunology in his research. His Transplantation study frequently links to other fields, such as Surgery. His research brings together the fields of Transplantation and Surgery. Oncology and Chemotherapy are two areas of study in which he engages in interdisciplinary research.
A majority of his Internal medicine research is a blend of other scientific areas, such as Oncology, Gastroenterology and Surgery. Gastroenterology and Internal medicine are two areas of study in which he engages in interdisciplinary work. His Surgery study frequently links to other fields, such as Transplantation. His Transplantation study frequently draws connections to adjacent fields such as Hematopoietic stem cell transplantation. His Biochemistry study frequently draws parallels with other fields, such as Gene and In vitro. Gene and Genetics are two areas of study in which he engages in interdisciplinary research. His research combines Stem cell and Genetics. He regularly ties together related areas like Biochemistry in his In vitro studies. In his research, Hermann Einsele performs multidisciplinary study on Immunology and Virus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress.
Biology of Blood and Marrow Transplantation (2009)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac.
Lancet Oncology (2014)
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.
Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger.
The landscape of genomic alterations across childhood cancers
Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter.
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann.
Journal of Clinical Oncology (2006)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: